Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

Silwan Chedid, Edgardo Rivera, Debbie K. Frye, Nuhad Ibrahim, Francisco Esteva, Vicente Valero, Gabriel Hortobagyi, Karl L. Mettinger, Massimo Cristofanilli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin analog that has exhibited antitumor activity in breast cancer patients during preclinical studies. Methods: Sixteen patients with metastatic breast cancer previously treated with anthracycline and taxane were utilized in the study. Orathecin was administered orally at 1.5 mg/m2/day for the first five consecutive days of the cycle followed by 2 days of rest on a 7-day schedule. The end points of the study were efficacy and toxicity. Results: The median age of the patients was 51 years (range, 35-73). Eight patients (50%) had multiple disease sites, and nine patients (56%) received more than three chemotherapy regimens. All patients were evaluated for toxicity, three patients were removed from the study for toxicity or disease progression prior to 8 weeks and were thus not evaluated for efficacy. The median follow-up was 110 days (range, 15-554). There were no responses to treatment. Five of the 13 evaluable patients (38%) had stable disease, eight (61%) had progressive disease. Most adverse events were mild to moderate in intensity. The median time to progression (TTP) for evaluable patients was 109 days (range, 56-374 days) (lower 95% C.I., 57 days). The median survival time was 272 days (lower 95% C.I., 209 days). Conclusions: Orathecin at the dose and regimen used in this study resulted in no objective tumor responses for this heavily pretreated population. Accurate risk stratification strategies can improve patients' selection and contribute to determine the appropriate benefit of therapies in MBC.

Original languageEnglish (US)
Pages (from-to)540-544
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume57
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Breast Neoplasms
Toxicity
Camptothecin
Chemotherapy
Anthracyclines
Tumors
rubitecan
Patient Selection
Disease Progression
Appointments and Schedules
Drug Therapy
Survival
Therapeutics
Population
Neoplasms
taxane

Keywords

  • 9-Nitro camptothecin
  • Metastatic breast cancer
  • Orathecin
  • Phase II trial
  • Rubitecan

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Chedid, S., Rivera, E., Frye, D. K., Ibrahim, N., Esteva, F., Valero, V., ... Cristofanilli, M. (2006). Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 57(4), 540-544. https://doi.org/10.1007/s00280-005-0064-x

Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. / Chedid, Silwan; Rivera, Edgardo; Frye, Debbie K.; Ibrahim, Nuhad; Esteva, Francisco; Valero, Vicente; Hortobagyi, Gabriel; Mettinger, Karl L.; Cristofanilli, Massimo.

In: Cancer Chemotherapy and Pharmacology, Vol. 57, No. 4, 04.2006, p. 540-544.

Research output: Contribution to journalArticle

Chedid, S, Rivera, E, Frye, DK, Ibrahim, N, Esteva, F, Valero, V, Hortobagyi, G, Mettinger, KL & Cristofanilli, M 2006, 'Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer', Cancer Chemotherapy and Pharmacology, vol. 57, no. 4, pp. 540-544. https://doi.org/10.1007/s00280-005-0064-x
Chedid, Silwan ; Rivera, Edgardo ; Frye, Debbie K. ; Ibrahim, Nuhad ; Esteva, Francisco ; Valero, Vicente ; Hortobagyi, Gabriel ; Mettinger, Karl L. ; Cristofanilli, Massimo. / Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. In: Cancer Chemotherapy and Pharmacology. 2006 ; Vol. 57, No. 4. pp. 540-544.
@article{3e4e4214556c4d319619232782c16409,
title = "Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer",
abstract = "Purpose: The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin analog that has exhibited antitumor activity in breast cancer patients during preclinical studies. Methods: Sixteen patients with metastatic breast cancer previously treated with anthracycline and taxane were utilized in the study. Orathecin was administered orally at 1.5 mg/m2/day for the first five consecutive days of the cycle followed by 2 days of rest on a 7-day schedule. The end points of the study were efficacy and toxicity. Results: The median age of the patients was 51 years (range, 35-73). Eight patients (50{\%}) had multiple disease sites, and nine patients (56{\%}) received more than three chemotherapy regimens. All patients were evaluated for toxicity, three patients were removed from the study for toxicity or disease progression prior to 8 weeks and were thus not evaluated for efficacy. The median follow-up was 110 days (range, 15-554). There were no responses to treatment. Five of the 13 evaluable patients (38{\%}) had stable disease, eight (61{\%}) had progressive disease. Most adverse events were mild to moderate in intensity. The median time to progression (TTP) for evaluable patients was 109 days (range, 56-374 days) (lower 95{\%} C.I., 57 days). The median survival time was 272 days (lower 95{\%} C.I., 209 days). Conclusions: Orathecin at the dose and regimen used in this study resulted in no objective tumor responses for this heavily pretreated population. Accurate risk stratification strategies can improve patients' selection and contribute to determine the appropriate benefit of therapies in MBC.",
keywords = "9-Nitro camptothecin, Metastatic breast cancer, Orathecin, Phase II trial, Rubitecan",
author = "Silwan Chedid and Edgardo Rivera and Frye, {Debbie K.} and Nuhad Ibrahim and Francisco Esteva and Vicente Valero and Gabriel Hortobagyi and Mettinger, {Karl L.} and Massimo Cristofanilli",
year = "2006",
month = "4",
doi = "10.1007/s00280-005-0064-x",
language = "English (US)",
volume = "57",
pages = "540--544",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

AU - Chedid, Silwan

AU - Rivera, Edgardo

AU - Frye, Debbie K.

AU - Ibrahim, Nuhad

AU - Esteva, Francisco

AU - Valero, Vicente

AU - Hortobagyi, Gabriel

AU - Mettinger, Karl L.

AU - Cristofanilli, Massimo

PY - 2006/4

Y1 - 2006/4

N2 - Purpose: The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin analog that has exhibited antitumor activity in breast cancer patients during preclinical studies. Methods: Sixteen patients with metastatic breast cancer previously treated with anthracycline and taxane were utilized in the study. Orathecin was administered orally at 1.5 mg/m2/day for the first five consecutive days of the cycle followed by 2 days of rest on a 7-day schedule. The end points of the study were efficacy and toxicity. Results: The median age of the patients was 51 years (range, 35-73). Eight patients (50%) had multiple disease sites, and nine patients (56%) received more than three chemotherapy regimens. All patients were evaluated for toxicity, three patients were removed from the study for toxicity or disease progression prior to 8 weeks and were thus not evaluated for efficacy. The median follow-up was 110 days (range, 15-554). There were no responses to treatment. Five of the 13 evaluable patients (38%) had stable disease, eight (61%) had progressive disease. Most adverse events were mild to moderate in intensity. The median time to progression (TTP) for evaluable patients was 109 days (range, 56-374 days) (lower 95% C.I., 57 days). The median survival time was 272 days (lower 95% C.I., 209 days). Conclusions: Orathecin at the dose and regimen used in this study resulted in no objective tumor responses for this heavily pretreated population. Accurate risk stratification strategies can improve patients' selection and contribute to determine the appropriate benefit of therapies in MBC.

AB - Purpose: The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin analog that has exhibited antitumor activity in breast cancer patients during preclinical studies. Methods: Sixteen patients with metastatic breast cancer previously treated with anthracycline and taxane were utilized in the study. Orathecin was administered orally at 1.5 mg/m2/day for the first five consecutive days of the cycle followed by 2 days of rest on a 7-day schedule. The end points of the study were efficacy and toxicity. Results: The median age of the patients was 51 years (range, 35-73). Eight patients (50%) had multiple disease sites, and nine patients (56%) received more than three chemotherapy regimens. All patients were evaluated for toxicity, three patients were removed from the study for toxicity or disease progression prior to 8 weeks and were thus not evaluated for efficacy. The median follow-up was 110 days (range, 15-554). There were no responses to treatment. Five of the 13 evaluable patients (38%) had stable disease, eight (61%) had progressive disease. Most adverse events were mild to moderate in intensity. The median time to progression (TTP) for evaluable patients was 109 days (range, 56-374 days) (lower 95% C.I., 57 days). The median survival time was 272 days (lower 95% C.I., 209 days). Conclusions: Orathecin at the dose and regimen used in this study resulted in no objective tumor responses for this heavily pretreated population. Accurate risk stratification strategies can improve patients' selection and contribute to determine the appropriate benefit of therapies in MBC.

KW - 9-Nitro camptothecin

KW - Metastatic breast cancer

KW - Orathecin

KW - Phase II trial

KW - Rubitecan

UR - http://www.scopus.com/inward/record.url?scp=30644463824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644463824&partnerID=8YFLogxK

U2 - 10.1007/s00280-005-0064-x

DO - 10.1007/s00280-005-0064-x

M3 - Article

C2 - 16193332

AN - SCOPUS:30644463824

VL - 57

SP - 540

EP - 544

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -